15 High-Growth Large-Cap Stocks to Invest In Now

13. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Market Capitalization: $37.29 Billion

Expected 5-Year Earnings Growth: 78.43%

Number of Hedge Fund Holders: 54

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the high-growth large-cap stocks to invest in now. On June 5, H.C. Wainwright reiterated a Buy rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and a $510 price target in response to the company inking a strategic collaboration with Inceptive Nucleics.

The two companies have inked a strategic collaboration to accelerate therapeutics innovation. Valued at up to $2 billion, the collaboration includes an upfront consideration of $30 million, comprising cash and the purchase of Inceptive equity. Inceptive is also entitled to additional payments on achieving preclinical regulatory and commercial sales milestones.

Alnylam Pharmaceuticals entered into a strategic collaboration to accelerate the development of its pipeline. Under the ‘Alnylam 2030’ framework, the company plans to expand to 10 tissue types and to over 40 clinical programs. H.C Wainwright expects the partnership with Inceptive to strengthen the company’s long-term innovation. In addition, it expects an Inceptive AI-driven RNA drug design approach to help reduce the risk associated with traditional trial-and-error drug discovery processes.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a biopharmaceutical company that pioneers RNA interference (RNAi) therapeutics. Their medicines work by “silencing” the genes that cause or contribute to disease, preventing the body from producing unwanted or harmful proteins before they can cause damage.